Adrenal medullary function and expression of catecholamine-synthesizing enzymes in mice with hypothalamic obesity.
The mechanisms underlying the onset of obesity are complex and not completely understood. An imbalance of autonomic nervous system has been proposed to be a major cause of great fat deposits accumulation in hypothalamic obesity models. In this work we therefore investigated the adrenal chromaffin cells in monosodium glutamate (MSG)-treated obese female mice. Newborn mice were injected daily with MSG (4 mg/g body weight) or saline (controls) during the first five days of life and studied at 90 days of age. The adrenal catecholamine content was 56.0% lower in the obese group when compared to lean controls (P < 0.0001). Using isolated adrenal medulla we observed no difference in basal catecholamine secretion percentile between obese and lean animals. However, the percentile of catecholamine secretion stimulated by high K+ concentration was lower in the obese group. There was a decrease in the tyrosine hydroxylase enzyme expression (57.3%, P < 0.004) in adrenal glands of obese mice. Interestingly, the expression of dopamine beta-hydroxylase was also reduced (47.0%, P < 0.005). Phenylethanolamine N-methyltransferase expression was not affected. Our results show that in the MSG model, obesity status is associated with a defective adrenal chromaffin cell function. We conclude that in MSG obesity the low total catecholamine content is directly related to a decrease of key catecholamine-synthesizing enzymes, which by its turn may lead to a defective catecholamine secretion.
Martins
Andréia C P
AC
Department of Cell Biology and Genetics, State University of Maringá, Maringá, PR, Brazil.
Souza
Kléber L A
KL
Shio
Marina T
MT
Mathias
Paulo C F
PC
Lelkes
Peter I
PI
Garcia
Raúl M G
RM
D000313:Adrenal Medulla / Q000201:enzymology / Q000378:metabolism / Q000503:physiopathology*; D000818:Animals; D002395:Catecholamines / Q000378:metabolism*; D004195:Disease Models, Animal; D004299:Dopamine beta-Hydroxylase / Q000096:biosynthesis; D005260:Female; D007027:Hypothalamic Diseases / Q000139:chemically induced / Q000150:complications*; D051379:Mice; D006899:Mixed Function Oxygenases / Q000096:biosynthesis*; D009765:Obesity / Q000201:enzymology / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D010625:Phenylethanolamine N-Methyltransferase / Q000096:biosynthesis*; D012970:Sodium Glutamate / Q000633:toxicity; D014446:Tyrosine 3-Monooxygenase / Q000096:biosynthesis
D002395:Catecholamines; D006899:Mixed Function Oxygenases; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase; D010625:Phenylethanolamine N-Methyltransferase; D012970:Sodium Glutamate